Pharma Exclusives Pressreleases
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Monday, March 30, 2026Biogen Inc Nasdaq BIIB today announced that the High Dose Regimen of SPINRAZA nusinersen which is comprised of mg mL and mg mL doses was approved by the US Food and Drug Administration
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Tuesday, March 24, 2026Gilead Sciences Inc Nasdaq GILD announced today it has entered into a definitive agreement to acquire Ouro Medicines a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases
Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.
Tuesday, March 24, 2026Thermo Fisher Scientific Inc NYSE TMO the world leader in serving science today announced the completion of its acquisition of Clario Holdings Inc a leading provider of endpoint data solutions for clinical trials for billion in cash plus potential a...
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Monday, March 23, 2026Lexicon Pharmaceuticals Inc Nasdaq LXRX and Novo Nordisk AS today announced that Novo Nordisk has initiated a Phase study with LX a firstinclass oral nonincretin development candidate
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
Wednesday, February 18, 2026Merck known as MSD outside of the US and Canada and Mayo Clinic the worlds topranked hospital system today announced a research and development agreement to apply artificial intelligence AI advanced analytics
Lilly to acquire Orna Therapeutics to advance cell therapies
Monday, February 09, 2026Eli Lilly and Company and Orna Therapeutics Inc a biotechnology company dedicated to engineering immune cells in vivo today announced entry into a definitive agreement for Lilly to acquire Orna
AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals
Thursday, January 29, 2026AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple nextgeneration therapies for obesity and type diabetes
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI
Tuesday, January 13, 2026NVIDIA and Eli Lilly and Company today announced a firstofitskind AI coinnovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry
Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI to Advance Scientific Instrumentation and Accelerate Laboratory Performance
Tuesday, January 13, 2026Thermo Fisher Scientific Inc the world leader in serving science announced a strategic collaboration with NVIDIA to power AIbased solutions and laboratory automation at scale The effort will leverage the NVIDIA Artificial Intelligence
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Monday, January 12, 2026Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA and Royalty Pharma plc Nasdaq RPRX today announced a funding agreement of up to million to accelerate the clinical development of Tevas antiIL antibody TEV...
